Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1031

    1.

    Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.

    Esteva FJ, Cheli CD, Fritsche H, Fornier M, Slamon D, Thiel RP, Luftner D, Ghani F.

    Breast Cancer Res. 2005;7(4):R436-43. Epub 2005 Apr 8.

    PMID:
    15987448
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer.

    Ali SM, Carney WP, Esteva FJ, Fornier M, Harris L, Köstler WJ, Lotz JP, Luftner D, Pichon MF, Lipton A; Serum HER-2/neu Study Group.

    Cancer. 2008 Sep 15;113(6):1294-301.

    PMID:
    18661530
    [PubMed - indexed for MEDLINE]
    Free Article
    3.

    HER-2/neu status of primary breast cancer and corresponding metastatic sites in patients with advanced breast cancer treated with trastuzumab-based therapy.

    Pectasides D, Gaglia A, Arapantoni-Dadioti P, Bobota A, Valavanis C, Kostopoulou V, Mylonakis N, Karabelis A, Pectasides M, Economopoulos T.

    Anticancer Res. 2006 Jan-Feb;26(1B):647-53.

    PMID:
    16739334
    [PubMed - indexed for MEDLINE]
    4.

    Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

    Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

    J Clin Oncol. 2003 Aug 1;21(15):2889-95.

    PMID:
    12885806
    [PubMed - indexed for MEDLINE]
    5.

    ADVIA Centaur HER-2/neu shows value in monitoring patients with metastatic breast cancer.

    Lüftner D, Cheli C, Mickelson K, Sampson E, Possinger K.

    Int J Biol Markers. 2004 Jul-Sep;19(3):175-82.

    PMID:
    15503818
    [PubMed - indexed for MEDLINE]
    6.

    [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].

    Svoboda M, Grell P, Simícková M, Fabian P, Petráková K, Palácová M, Macková D, Trojanec R, Hajdúch M, Pavlík T, Nenutil R, Vyzula R.

    Klin Onkol. 2008;21(6):348-58. Czech.

    PMID:
    19382598
    [PubMed - indexed for MEDLINE]
    7.

    Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer.

    Köstler WJ, Schwab B, Singer CF, Neumann R, Rücklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC.

    Clin Cancer Res. 2004 Mar 1;10(5):1618-24.

    PMID:
    15014012
    [PubMed - indexed for MEDLINE]
    Free Article
    8.

    Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.

    Müller V, Witzel I, Lück HJ, Köhler G, von Minckwitz G, Möbus V, Sattler D, Wilczak W, Löning T, Jänicke F, Pantel K, Thomssen C.

    Breast Cancer Res Treat. 2004 Jul;86(1):9-18.

    PMID:
    15218357
    [PubMed - indexed for MEDLINE]
    9.

    HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.

    Hoopmann M, Neumann R, Tanasale T, Schöndorf T.

    Anticancer Res. 2003 Mar-Apr;23(2A):1031-4.

    PMID:
    12820343
    [PubMed - indexed for MEDLINE]
    10.

    [The predictive and monitoring value of serum HER2/NEU in breast cancer under trastuzumab therapy].

    Couto Mdo R, Pinto D, Oliveira J, Monteiro A, Pereira D, Medeiros R, Rodrigues H.

    Acta Med Port. 2011 Jan-Feb;24(1):5-16. Epub 2011 Feb 28. Portuguese.

    PMID:
    21672436
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy.

    Sandri MT, Johansson HA, Zorzino L, Salvatici M, Passerini R, Maisonneuve P, Rocca A, Peruzzotti G, Colleoni M.

    Cancer. 2007 Aug 1;110(3):509-17.

    PMID:
    17559147
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer.

    Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N, Kasumi F, Akiyama F, Sakamoto G, Imai T, Nakao A, Hatake K.

    Tumori. 2004 Jan-Feb;90(1):40-3.

    PMID:
    15143970
    [PubMed - indexed for MEDLINE]
    13.

    Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastuzumab-based therapy in patients with metastatic breast cancer.

    Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC, Singer CF.

    Int J Cancer. 2006 Mar 1;118(5):1126-34.

    PMID:
    16161043
    [PubMed - indexed for MEDLINE]
    14.

    Insulin-like growth factor-1 receptor (IGF-1R) expression does not predict for resistance to trastuzumab-based treatment in patients with Her-2/neu overexpressing metastatic breast cancer.

    Köstler WJ, Hudelist G, Rabitsch W, Czerwenka K, Müller R, Singer CF, Zielinski CC.

    J Cancer Res Clin Oncol. 2006 Jan;132(1):9-18. Epub 2005 Sep 24.

    PMID:
    16184380
    [PubMed - indexed for MEDLINE]
    15.

    Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

    Nishimura R, Okumura Y, Arima N.

    Breast Cancer. 2008;15(1):57-64.

    PMID:
    18224396
    [PubMed - indexed for MEDLINE]
    16.

    EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.

    Gori S, Sidoni A, Colozza M, Ferri I, Mameli MG, Fenocchio D, Stocchi L, Foglietta J, Ludovini V, Minenza E, De Angelis V, Crinò L.

    Ann Oncol. 2009 Apr;20(4):648-54. Epub 2009 Feb 2.

    PMID:
    19188134
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study.

    Burstein HJ, Keshaviah A, Baron AD, Hart RD, Lambert-Falls R, Marcom PK, Gelman R, Winer EP.

    Cancer. 2007 Sep 1;110(5):965-72.

    PMID:
    17614302
    [PubMed - indexed for MEDLINE]
    Free Article
    19.

    Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

    Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, dela Rosa C, Tietje K, Link J, Waisman J, Salazar LG.

    J Clin Oncol. 2009 Oct 1;27(28):4685-92. Epub 2009 Aug 31.

    PMID:
    19720923
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.

    Stickeler E, Klar M, Watermann D, Geibel A, Földi M, Hasenburg A, Gitsch G.

    Breast Cancer Res Treat. 2009 Oct;117(3):591-8. Epub 2009 Jan 21.

    PMID:
    19156515
    [PubMed - indexed for MEDLINE]

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk